Edwards Lifesciences recently announced that it would acquire Innovalve Bio Medical, an early-stage transcatheter mitral valve replacement (“TMVR”) company. Edwards had the option to acquire Innovalve following an initial investment in 2017. The acquisition is expected to close by the end of the year.
Regarding the acquisition, Daveen Chopra, head of Edwards’ transcatheter mitral and tricuspid therapies product group, stated:
We believe the Innovalve technologies, paired with Edwards’ deep mitral expertise, will enable a TMVR platform that will expand the treatable population…. Edwards’ SAPIEN M3 remains on track to become the first approved transfemoral TMVR system in Europe by the end of 2025.
Innovalve, founded in 2017 at the Sheba Medical Center in Israel, currently makes the Innostay TMVR system. According to Innovalve, the Innostay “utilizes a unique rotational maneuver of specially designed arms which lead to the native Mitral Valve tissue to wrap around the Valve prosthesis, providing firm anchoring and sealing, leading to significant improvement in post-procedural symptoms of mitral regurgitation.” Innovalve is conducting an early feasibility study to evaluate the safety and performance of the Innostay in treating mitral valve regurgitation. That study is expected to be completed in September 2028.
Tags
Acquisitions, Edwards Lifesciences, Innovalve Bio Medical, TMVR, transcatheter mitral valve replacement
By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
